Novelties in the field of anti-infective compounds in 1999

Clinical Infectious Diseases

Volumn 31, Issue 6, 2000, Pages 1423-1466

  Bryskier, André ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; NEW DRUG;

ANIMAL; BACTERIUM; CHEMISTRY; DRUG EFFECT; HUMAN; INFECTION; PROTOZOON; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DRUGS, INVESTIGATIONAL; HUMANS; INFECTION; PROTOZOA;

EID: 0034573088     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317490     Document Type: Article

References (16)

1. Bryskier A. Novelties in the field of anti-infectives in 1997. Clin Infect Dis 1998;27:865-83.
2. Bryskier A. Novelties in the field of anti-infectives in 1998. Clin Infect Dis 1999;29:632-58.
3. Hayashi N, Oshita Y, Amano H, Hirao Y, Nino Y, Yazaki A. WQ 3330 and WQ 2942, structure activity relationships of novel 8-methyl quinolones containing an aminophenyl group at the N-1 position [abstract 557]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:307.
4. Bryskier A. Novelties in the field of fluoroquinolones. Exp Opin Invest Drugs 1997;6:1227-45.
5. Ledoussal B, Almstead JK, Flaim SM, et al. Novel nonfluoroquinolones (NFQs), structure, activity, and design of new potent and safe agents [abstract 544]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:3031.
6. Hannah-Hardy J, Murphy V, Kuzmak B, et al. Acute IV toxicity and clastogenicity of novel 8-methoxy-nonfluoroquinolones compared with 8-methoxy-fluoroquinolones [abstract 553]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:306.
7. Murphy V, Hannah-Hardy J, Murli H, et al. Preliminary toxicology of a series of nonfluoroquinolones (NFQs) [abstract 554]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:306.
8. Brown SD, Barry AL, Fuchs PC. In vitro antibacterial activity of a series of novel nonfluoroquinolones (NFQs) against bacterial pathogens [abstract 549]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:305.
9. Roychoudhury S, Makin KM, McIntosh EJ, et al. In vitro antibacterial activity of a series of nonfluoroquinolones (NFQs) against penicillin-and quinolone-resistant strains of Streptococcus pneumoniae [abstract 548], In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:304.
10. Mallalieu NL, Ellis DH, Zoutendam PH, et al. Preclinical pharmacokinetics of a series of nonfluoroquinolones (NFQs) [abstract 550]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:305.
11. Allemandi DA, Alovero FL, Manzor H. In vitro activity of new sulfanilyl fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 1994;34:261-5.
12. Alovero FL, Pan XS, Morris JE, Manzor H, Fischer LM. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin changes its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother 2000;44:320-5.
13. Hayashi K, Kito T, Mitsuyama J, et al. Preparation of quinolones carboxylic acid derivatives as antibiotics. PCT Intern Appl 1999:WO/9951/588.
14. Bryskier A, Labro MT. Quinolones and malaria: an avenue for the future. Quinolones Bull 1990;6:1-4.
15. Brun-Pascaud M, Fay M, Zhong M, Bauchet J, Dux-Guyot A, Pocidalo JJ. Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1992;36:470-2.
16. Khan AA, Araujo FG, Remington JS. Gatifloxacin is active against Toxoplasma gomdii [abstract 1848]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington, DC: American Society for Microbiology, 1999:728.